Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - valaciclovir - film-coated tablet - 500 milligram(s) - nucleosides and nucleotides excl. reverse transcriptase inhibitors; valaciclovir

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

aurobindo sa-nv - valaciclovir hydrochloride 305,85 mg - eq. valaciclovir 250 mg - film-coated tablet - 250 mg - valaciclovir hydrochloride 305.85 mg - valaciclovir

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

aurobindo sa-nv - valaciclovir hydrochloride 1223,4 mg - eq. valaciclovir 1000 mg - film-coated tablet - 1000 mg - valaciclovir hydrochloride 1223.4 mg - valaciclovir

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

aurobindo sa-nv - valaciclovir hydrochloride 611,7 mg - eq. valaciclovir 500 mg - film-coated tablet - 500 mg - valaciclovir hydrochloride 611.7 mg - valaciclovir

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - valaciclovir hydrochloride 556,28 mg - eq. valaciclovir 500 mg - film-coated tablet - 500 mg - valaciclovir hydrochloride 556.28 mg - valaciclovir

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - valaciclovir, quantity: 500 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; povidone; crospovidone; magnesium stearate; indigo carmine aluminium lake; titanium dioxide; hypromellose; polysorbate 80; macrogol 6000; macrogol 400 - for the treatment of herpes zoster (shingles) in adult patients who commence therapy within 72 hours of the onset of rash. treatment of ophthalmic zoster. treatment of clinical episodes of genital herpes simplex infections. for the prevention of recurrent genital herpes in immunocompromised patients with creatinine clearance of > 15 ml/min. for the reduction of transmission of genital herpes in patients suffering from recurrent genital herpes. in addition to therapy with valaciclovir, it is recommended that patients use safer sex practices (see precautions). for prophylaxis of cytomegalovirus (cmv) infection and disease following solid organ transplantation in patients at risk of cmv disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - valaciclovir hydrochloride, quantity: 556 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; povidone; magnesium stearate; crospovidone; titanium dioxide; hypromellose; polysorbate 80; macrogol 400; indigo carmine aluminium lake - for the treatment of herpes zoster (shingles) in adult patients who commence therapy within 72 hours of the onset of rash.,for the treatment of ophthalmic zoster.,for the treatment of recurrent herpes labialis (cold sores),for the treatment of clinical episodes of genital herpes simplex infections.,for the prevention of recurrent genital herpes.,reduction of transmission of genital herpes in patients suffering from recurrent genital herpes. in addition to therapy with valaciclovir, it is recommended that patients use safer sex practices. ,prophylaxis of cytomegalovirus (cmv) infection and disease following solid organ transplantation in patients at risk of cmv disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - valaciclovir hydrochloride, quantity: 1112 mg - tablet, film coated - excipient ingredients: povidone; microcrystalline cellulose; crospovidone; magnesium stearate; titanium dioxide; hypromellose; polysorbate 80; macrogol 400; indigo carmine aluminium lake - for the treatment of herpes zoster (shingles) in adult patients who commence therapy within 72 hours of the onset of rash.,for the treatment of ophthalmic zoster.,for the treatment of recurrent herpes labialis (cold sores),for the treatment of clinical episodes of genital herpes simplex infections.,for the prevention of recurrent genital herpes.,reduction of transmission of genital herpes in patients suffering from recurrent genital herpes. in addition to therapy with valaciclovir, it is recommended that patients use safer sex practices. ,prophylaxis of cytomegalovirus (cmv) infection and disease following solid organ transplantation in patients at risk of cmv disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - valaciclovir hydrochloride, quantity: 1112 mg - tablet, film coated - excipient ingredients: magnesium stearate; crospovidone; povidone; microcrystalline cellulose; titanium dioxide; hypromellose; polysorbate 80; macrogol 400; indigo carmine aluminium lake - for the treatment of herpes zoster (shingles) in adult patients who commence therapy within 72 hours of the onset of rash.,for the treatment of ophthalmic zoster.,for the treatment of recurrent herpes labialis (cold sores),for the treatment of clinical episodes of genital herpes simplex infections.,for the prevention of recurrent genital herpes.,reduction of transmission of genital herpes in patients suffering from recurrent genital herpes. in addition to therapy with valaciclovir, it is recommended that patients use safer sex practices. ,prophylaxis of cytomegalovirus (cmv) infection and disease following solid organ transplantation in patients at risk of cmv disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - valaciclovir hydrochloride monohydrate 1223.4mg equivalent to valaciclovir base 1000 mg - film coated tablet - 1000 mg - active: valaciclovir hydrochloride monohydrate 1223.4mg equivalent to valaciclovir base 1000 mg excipient: magnesium stearate microcrystalline cellulose opadry white y-5-7068 povidone - valaciclovir actavis is indicated for the treatment of herpes zoster (shingles) and the reduction of zoster - associated pain, which includes acute and post herpetic neuralgia, when given to immunocompetent patients in infection of less than 72 hours duration.